News and Events

Halo Pharma Set to Launch New Sterile Injectable Manufacturing Capabilities at Whippany Facility $45 million investment delivers critical domestic sterile manufacturing capacity to pharmaceutical partners Dozens attend open house prior to GMP qualification process to get a sneak peek at the new sterile injectable line Whippany, NJ – August 20, 2026 – Halo Pharma, a leading CDMO specializing in drug product pharmaceutical development and manufacturing services, is entering the final operational stages to activate its new sterile injectable manufacturing line.

Inside Halo’s New Fill-Finish Platform Glenn Herring took PharmTech inside our new sterile fill-finish manufacturing platform to show how we are expending capabilities and positioning Halo to serve both clinical and commercial sterile injectable programs. Watch the interview to get Glenn’s insights: https://www.pharmtech.com/view/inside-halos-fill-finish-platform

Three Formats, One Platform: Halo’s New Sterile Fill-Finish Line Halo Pharma is building to close the gap in the U.S. injectable supply chain, and PharmTech spoke with Group CEO Lee Karras about our expanded capabilities and what it means for our customers. Hear what Lee had to say at https://www.pharmtech.com/view/three-formats-one-platform-halos-sterile-fill-finish-line  

Halo Pharma Emerges as Standalone CDMO Following Siegfried Acquisition of Noramco Independent CDMO positioned for growth in sterile injectables and other complex drug product formats Over $30 million investment plan underway to establish sterile vial, prefilled syringe, and cartridge manufacturing in Whippany, NJ Lee Karras (previously CEO of Noramco) named Halo Pharma’s CEO to lead next phase of expansion Whippany, NJ – May 1, 2026 – Halo Pharma (the “Company”), a leading CDMO partner to the pharmaceutical industry and previous

Apotex Announces Strategic U.S. Sterile Filling Partnership with Halo Pharmaceuticals Weston, Florida and Whippany, New Jersey — April 14, 2026 – Apotex Corp. today announced that it has secured a strategic sterile filling partnership with Halo Pharmaceuticals through an investment that provides Apotex with access to a significant portion of the overall sterile injectable filling capacity currently being installed and qualified at Halo’s Whippany, New Jersey facility. This access is intended to support Apotex’s sterile injectable manufacturing network and signals

Halo Pharma Executive Chairman Lee Karras says escalating equipment and component costs are the two biggest challenges facing parenteral/sterile drug product manufacturers.